Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, et al. N Engl J Med 2021 Jun 28. doi: 10.1056/NEJMoa2108269.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med 2021 Jun 28. doi: 10.1056/NEJMoa2108269.
PMID: 34215025